Pds biotech to host key opinion leader event to discuss versamune® hpv for the treatment of hpv16+ hnscc

Event to discuss the changing landscape of hnscc in context with the merck kn-689 study and the rapidly increasing incidences of hpv16-positive hnscc in the united states and europe
PDS Ratings Summary
PDS Quant Ranking